Avanos Medical Inc

AVNS remains in a Stage 2 advancing phase with its long-term uptrend intact and medium-term bullish permission. The active Lockout Rally pattern has driven price into a tight plateau at new highs, with EMAs flattening but holding support. Under the Lockout Rally override, short-term bias is bullish despite extended conditions, justifying aggressive entry now. Execution will target continuation participation on shallow pullbacks into the 9/20 EMA zone or on a break of the base of the consolidation.

• ↑2025 revenue $701M exceeds guidance; specialty nutrition sales +8% organic.
• ↑Adjusted EPS $0.94 and FCF ~$40M reflect solid cash generation.
• ↓Gross margin 54.6% hit by tariffs; 2026 tariff costs ~$30M.